Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276250 | 0.93 | TP53 (0.54) | TP53OPRM1FDPSCA2CA1 | |
| SCHEMBL277152 | 0.91 | TP53 (0.52) | TP53OPRM1FDPSCA2CA1 | |
| SCHEMBL6152723 | 0.91 | TP53 (0.52) | TP53OPRM1FDPSCA2CA1 | |
| SCHEMBL276559 | 0.91 | TP53 (0.52) | TP53OPRM1FDPSCA2CA1 | |
| SCHEMBL77044 | 0.91 | TP53 (0.52) | TP53OPRM1FDPSCA2CA1 | |
| SCHEMBL222995 | 0.84 | — | — | |
| SCHEMBL451141 | 0.79 | TP53 (0.48) | TP53SLC15A1OPRM1DNM1TSHR | |
| SCHEMBL329736 | 0.77 | TP53 (0.46) | TP53SLC15A1OPRM1DNM1TSHR | |
| SCHEMBL5637608 | 0.77 | TP53 (0.46) | TP53SLC15A1OPRM1DNM1TSHR | |
| SCHEMBL6113068 | 0.75 | TP53 (0.45) | TP53SLC15A1OPRM1DNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | Sumitomo Pharma Co., Ltd. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4071239-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | Sumitomo Pharma Co., Ltd. (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-114901810-A | Method for culturing hematopoietic stem cells | 住友制药株式会社 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021132627-A1 | METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS | 大日本住友製薬株式会社 | 2021-07-01 | — | — | WO | disclosed |
| EP-3191471-B1 | 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-9550754-B2 | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-24 | — | — | US | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| EP-1085009-A1 | INDAN DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-6066631-A | Chroman derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| EP-0934296-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-08-11 | — | — | EP | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| WO-1998004542-A1 | CHROMAN DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-05 | — | — | WO | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094952-A1 | Method for Culturing Hematopoietic Stem Cells | HCLS1, KIT, MCL1 | TP53 2593/4885SLC15A1 862/4885OPRM1 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.